Income Statement (TTM)
Cordyceps Sunshine Biotech Holdings Co., Ltd. Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.
All numbers are times 1,000,000 except per share units.
|
2020 12-31 |
2021 12-31 |
2022 03-31 |
2022 06-30 |
2022 09-30 |
2022 12-31 |
2023 09-30 |
2023 12-31 |
2024 12-31 |
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 |
| Change (%) | 335.13 | 8.42 | 7.77 | -59.89 | 8.90 | 126.35 | -13.12 | 42.03 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| Cost Of Sales | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 |
| Change (%) | 1,631.17 | 9.69 | 8.84 | -62.33 | 8.59 | 16.55 | -80.67 | 519.67 | |
| % of Revenue | 30.17 | 120.04 | 121.45 | 122.66 | 115.18 | 114.86 | 59.14 | 13.16 | 57.42 |
| Gross Operating Profit | 0 | -0 | -0 | -0 | -0 | 0 | 0 | 1 | 1 |
| Change (%) | -224.88 | 16.05 | 13.83 | -73.13 | -163.24 | 949.23 | 84.65 | -30.35 | |
| % of Revenue | 69.83 | -20.04 | -21.45 | -22.66 | -15.18 | 8.81 | 40.86 | 86.84 | 42.58 |
| SG&A | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Change (%) | 116.66 | 7.01 | 6.41 | 50.87 | -7.94 | -0.90 | 26.61 | 33.26 | |
| % of Revenue | 61.99 | 30.86 | 30.46 | 30.08 | 113.14 | 95.64 | 41.87 | 61.02 | 57.25 |
| R&D | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Change (%) | 244.81 | 71.00 | -91.52 | 845.59 | 0.00 | ||||
| % of Revenue | 2.85 | 9.06 | 14.38 | 3.04 | 26.39 | 11.66 | |||
| OpEx | 0 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 |
| Change (%) | 617.79 | 13.44 | 11.85 | -44.52 | 14.31 | 7.46 | -44.18 | 119.55 | |
| % of Revenue | 93.52 | 154.27 | 161.41 | 167.52 | 231.69 | 243.21 | 115.47 | 74.18 | 114.67 |
| Operating Income | 0 | -0 | -1 | -1 | -1 | -0 | -0 | 0 | -0 |
| Change (%) | -3,743.15 | 22.69 | 18.49 | -21.76 | -23.51 | -62.16 | -245.03 | -180.72 | |
| % of Revenue | 6.48 | -54.27 | -61.41 | -67.52 | -131.69 | -92.50 | -15.47 | 25.82 | -14.67 |
| Interest Expense | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Change (%) | -59.41 | 70.33 | 41.29 | -87.46 | 1,825.21 | -0.00 | -44.59 | -57.12 | |
| % of Revenue | -15.06 | -1.40 | -2.21 | -2.89 | -0.90 | -15.99 | -7.07 | -4.51 | -1.36 |
| Net Income | -0 | -0 | -1 | -1 | -1 | -1 | -0 | 1 | -0 |
| Change (%) | 2,329.04 | 24.89 | 19.93 | 9.86 | -10.88 | -68.53 | -431.68 | -130.10 | |
| % of Revenue | -10.00 | -55.84 | -64.32 | -71.58 | -196.06 | -160.45 | -22.31 | 85.16 | -18.05 |
Source: Capital IQ
